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Abstract. Genomic profiling was performed on ex-
plantsoflateproliferativephasehumanendometrium
after 24-h treatment with progesterone (P) or oestra-
diol and progesterone (17b-E2+P) and on explants of
menstrualphaseendometriumtreatedwith17b-E2+P.
Gene expression was validated with real-time PCR in
the samples used for the arrays, in endometrium
collected from early and mid-secretory phase endo-
metrium,andinadditionalexperimentsperformed on
new samples collected in the menstrual and late
proliferative phase. The results show that late prolif-
erativephasehumanendometriumismoreresponsive
toprogestinsthanmenstrualphaseendometrium,that
the expression of several genes associated with
embryo implantation (i.e. thrombomodulin, mono-
amine oxidase A, SPARC-like 1) can be induced by P
in vitro, and that genes that are fully dependent on the
continuous presence of 17b-E2 during P exposure can
be distinguished from those that are P-dependent to a
lesser extent. Therefore, 17b-E2 selectively primes
implantation-related genes for the effects of P.
Keywords. human endometrium, explant cultures, global gene expression, oestradiol, progesterone.
Introduction
Optimal development of the endometrium is an
essentialprerequisiteforsuccessfulblastocystimplan-
tation. Progesterone (P) is essential for secretory
differentiation of endometrium, and the need for
oestrogen in cooperation with P in regulating the
implantation process is species-specific [1]. Our
current knowledge of the cellular and molecular
events orchestrating endometrial growth and differ-
entiation prior to implantation is limited.
In the natural cycle, the human endometrium is
receptive during a short period, approximately 19 to
24 daysaftertheonsetofmenstruation[2–6].Priorto
and during this period, the endometrium undergoes
extensive morphological and physiological changes to
facilitate implantation of the embryo [2, 6, 7]. These
changesaretightlycontrolledbyoestrogenandP[6,8,
9]. The responsiveness of the endometrium to P is
partlydependentuponthepre-ovulatorychangesthat
have occurred under the influence of oestrogen. This
isillustratedbythefactthathighoestrogenlevelsand/
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Cellular and Molecular Life Sciencesor prolonged oestrogen exposure accelerates endo-
metrial maturation, thus disturbing the synchrony of
embryo and endometrial development and subse-
quent implantation [10, 11]. Currently, there is no
clear definition and understanding of human endo-
metrial maturation and only limited knowledge about
the cellular mechanisms involved. We define mature
endometrial tissue as the physiological state of the
human endometrium that allows a correct response to
the luteal P, resulting in implantation of the embryo
and maintenance of pregnancy.
Our limited understanding of the processes underlying
endometrial maturation and P-controlled differentiation
priortoandduringimplantationislargelyduetothelackof
relevant model systems to evaluate endometrial responses
under physiologically relevant conditions. Previous work
has demonstrated that explant culture of human endome-
trial tissue is a suitable model to study the response to
oestrogen and P, most likely due to the preservation of the
tissue context [12–14]. Using this model we showed
previously that the responsiveness of the endometrium to
oestrogen changes throughout the proliferative phase with
regard to the regulation of gene expression and prolifer-
ation [12].
The present study was designed to gain more insight
into the responses of human endometrium to P with
regard to gene expression and into the influence of
17b-oestradiol (17b-E2) on this process. To this end,
global gene expression analysis was performed on
human endometrial tissue fragments collected from
themenstrualandlateproliferativephasesaftershort-
term culture in the presence of P and 17b-E2.
Materials and methods
Human endometrial tissue. Endometrial tissue was collected from
26 women (20–45 years of age) with regular menstrual cycles who
underwent surgery for benign indications. The tissue was collected
from hysterectomy specimens for benign indications or by pipelle
biopsies during laparoscopy for sterilisation (Pipelle catheter,
Unimar Inc., Prodimed, Neuilly-Enthelle, France). It was docu-
mentedthatthewomenwerenotonanykindofsteroidmedication.
All women who agreed to participate in the study signed an
informed consent form according to a protocol approved by the
Medical Ethical Committee of the Academic Hospital Maastricht.
Tissue was transported to the laboratory in DMEM/Ham s F12
medium on ice. A portion of each sample was fixed in 10%
buffered formalin for evaluation by histology. The endometrium
wasdatedaccordingtoclinicalinformationwithrespecttothestart
ofthelastmenstrualperiod,whichwasreconfirmedbyhistological
examinationofthetissue [15]. Ofthe 26biopsyspecimens, 11were
collected in the proliferative phase [menstrual phase, cycle day
(CD)1–5, n=6; late proliferative phase, CD11–14, n=5], and 15
were collected in the secretory phase [early secretory (ES),
CD15–18, n=7; mid-secretory (MS), CD19–24, n=8]. Of the 11
biopsy specimens collected from the proliferative phase, 4 were
used for microarray studies, and 7 were used for validation
purposes with real-time PCR analysis. The biopsy specimens
collected from the secretory phase were used for validation only.
Explant cultures. Human endometrium explant cultures were
prepared from menstrual phase and late proliferative phase
endometrium as described by Punyadeera et al. [16]. In brief,
human endometrial tissue was cut into 2–3 mm
3 pieces. A total of
24 explants were placed in Millicell-CM culture inserts (0.4 mm
pore size, 30 mm diameter; Millipore, France) in 6-well plates
containing 1.2 ml phenol red-free DMEM/Ham s F12 medium
(Life Technologies, Grand Island, NY), supplemented with L-
glutamine (1%), penicillin and streptomycin (1%, P/S). Cultures
were performed for 24 h. Previous experiments have shown that
collagenase activity remains very low in proliferative endometrial
tissueduringthefirst24 hofculture[17]andthatthetissueviability
is not affected after 24 h of culture [13].
The explants prepared from late proliferative phase endometrium
were cultured in the presence of vehicle (0.1% ethanol), 17b-E2
and P (1 nM each), or P alone (1 nM). The 17b-E2 was included to
maintaintheinvivooestrogensupport.Inordertomakeinferences
with regard to the responsiveness of the endometrium before and
afterprolongedinvivooestrogenexposure,wealsotreatedexplant
cultures prepared from menstrual phase endometrium (CD3 and
CD4) with 17b-E2 and P. To test the importance of 17b-E2 in the
response of late proliferative phase endometrium to P, 17b-E2 was
also omitted from some cultures. The steroid hormones were
provided by Organon N.V. (Oss, The Netherlands).
Total RNA extraction and cDNA synthesis. Total cellular RNA
from explants was extracted using the SV total RNA isolation kit
(Promega, USA) according to the manufacturer s protocol, with
slight modifications: The concentration of DNase-1 during DNase
treatment of the RNA samples was doubled, and the incubation
time was extended by 15 min in order to completely remove
genomic DNA. Total RNA was eluted from the column in 50 ml
RNase-free water and stored at 708C until further analysis. The
quality of the RNA samples was determined with the Agilent
bioanalyzer 2100 lab-on-a-chip (Agilent, USA). All the samples
analysed gave 28S to 18S ratios higher than 1.5. PCR for a
housekeeping gene, GAPDH, was performed to confirm that the
RNA samples were free of genomic DNA.
Total RNA (1 mg) was incubated with random hexamers (1 mg/ml,
Promega) at 708C for 10 min. The samples were chilled on ice for
5 min. To this mixture, a reverse transcriptase (RT) mix consisting
of 5  RT buffer (4 ml), 10 mM dNTP mix (1 ml; Pharmacia,
Uppsala, Sweden), 0.1 M DTT (2 ml; Invitrogen, CA, USA), and
superscript II reverse transcriptase (200 U/ml; Invitrogen) was
added, and the samples were incubated at 428C for 1 h, after which
the reverse transcriptase was inactivated by heating the samples at
958Cfor5 min.ThecDNAwasstoredat208Cuntilfurtheruse.In
each real-time PCR reaction, 50 ng cDNA template was used.
Affymetrix gene chip microarrays. Pooling of the RNA samples
was performed according to the phase of the menstrual cycle and
treatment conditions, i.e. two RNA samples from the menstrual
phase (CD3 and CD4) and two RNA samples from the late
proliferative phase (CD12 and CD13) were pooled. cRNA was
generated from the pooled RNA and was labelled with biotin
according to the Affymetrix protocol (Santa Clara, USA). cDNA
was hybridised to the Affymetrix HU-133A chips, which contains
approximately 22 000 human oligonucleotide probe sets, including
68 controls. The chip hybridisations were carried out in triplicate.
After washing, the chips were scanned and analysed using the
MicroArray suite MAS5. A detail description of the Affymetrix
chip content is available at the NetAffy analysis web page (http://
www.affymetrix.com/analysis/index.affx).
Microarraydataanalysis. Followinggene chip dataqualitycontrol,
datafiles(.EXP,.DAT,.CEL)generatedbyMAS5weretransferred
by FTP to the server housing the Rosetta Resolver Gene
Expression Data Analysis System. Rosetta Resolver uses Affyme-
trix gene chip error models to transform the raw data into a
processedformthatcan beusedin variousexpressionanalysesand
allows normalization of sample data of triplicate hybridizations
using one-way analysis of variance (ANOVA) [18]. Changes in
expressionlevelsbetweenthecontrolandthetreatedsampleswere
calculatedusingtwocriteria:(1)theabsolutefoldchange(>2-fold)
1010 H. Dassen et al. Steroid regulation of gene expression in human endometrium(e.g. the ratio between treated and control samples) and (2) a
corresponding p-value less than 0.01.
The use of microarrays results in a massive amount of data, which
requires special tools to filter and extract relevant information. By
combining the fold changes or log ratios and the p-value, we
generated a so-called significance code, which simplifies the
selection and extraction of genes of interest, especially when
analyzing various conditions. The significance code assigned to the
genes was based on ANOVA-retrieved p-values and up- or down-
regulationcomparedtotheuntreatedsamples.A significancecode
of1(increasedorup-regulated)wasusedforgeneswithp<0.01and
a log ratio >0; a significance code of 1 (decreased or down-
regulated) was used for genes with p<0.01 and log ratio <0. For
genes that didn t show significant regulation, the significance code
was 0 (log ratio =0 and p>0.01 independent of log ratio).
Data were then exported from Rosetta Resolver to the Spotfire
decisionsite7.1(Spotfire,Gçteborg,Sweden),inwhichgenesetsof
interest were visualized and subsequently selected. Data were
analyzed through the use of Ingenuity Pathways Analysis (IPA,
Ingenuity
  Systems, www.ingenuity.com). The data set containing
the significantly up- and down-regulated genes and the corre-
sponding expression values were uploaded into the application.
Each gene identifier was mapped to its corresponding gene object
in the Ingenuity Pathways Knowledge Base. These genes, called
focus genes, were overlaid onto a global molecular network
developed from information contained in the Ingenuity Pathways
Knowledge Base. Networks of these focus genes were then
algorithmically generated based on their connectivity.
A network is a graphical representation of the molecular relation-
shipsbetweengeneproducts.Thegeneproductsarerepresentedas
nodes, and the biological relationship between two nodes is
represented as a line. All lines are supported by at least one
referenceinliterature,textbook,orcanonicalinformationstoredin
theIngenuityPathwaysKnowledgeBase.Theintensityofthenode
colour indicates the degree of up- (red) or down- (green)
regulation.Nodesaredisplayedusingvariousshapesthatrepresent
the functional class of the gene product.
Validation of array data using real-time PCR analysis. A selection
of genes was validated with q-PCR to confirm expression in the
samplesusedformicroarrayanalysis.Inaddition,theexpressionof
thesegeneswasevaluatedinanindependentseriesofexperiments.
To confirm that the genes induced by P in vitro are indeed up-
regulated during the implantation window, we also assessed their
expression levels in endometrial tissue collected in the ES and MS
phases of the cycle.
Primers and probes were purchased from Perkin-Elmer Applied
Biosystems as pre-developed assays. Human cyclophilin A was
selected as an endogenous RNA control in order to normalize for
differences in the amount of total RNA added to each reaction.
Uncultured human endometrial tissue was included as a positive
control. All PCR reactions were performed using an ABI Prism
7700 sequence detection system (Perkin-Elmer Applied Biosys-
tems). The thermal cycling conditions comprised an initial decon-
tamination step at 508C for 2 min, a denaturation step at 958C for
10 min, and 40 cycles of 15 s at 958C, followed by 1 min at 608C.
Experiments were performed for each sample in duplicate.
Quantitative values were obtained from the threshold cycle
number (Ct), at which the increase in the signal associated with
exponential growth of PCR products was first detected with the
ABIPrism7700sequencedetectorsoftware(Perkin-Elmer,Foster
city, CA) The fold-change in expression was calculated using the
DD Ct method, with cyclophilin A mRNA as an internal control
[19].Foradetaileddescriptionoftheprocedure,pleaserefertothe
ABI user manual (http://www.uk1.unifreiburg.de/core/facility/tag-
man/user_bulletin_2.pdf).
Statistical analysis of real-time PCR results. Statistical tests were
carried out using the SPSS 11 (SPSS Inc., Chicago, IL) statistical
analysis package. The effects of 17b-E2+P and P alone on cultured
explants were analysed using the nonparametric paired Wilcoxon
signed rank test at a confidence level of 95%. The nonparametric
unpaired Mann-Whitney U test at a confidence level of 95% was
employed to analyse the real-time PCR data generated from
uncultured ES phase endometrial tissue and uncultured MS phase
endometrial tissue.
Results
Validation of array data with quantitative real-time
PCR. Eight genes were selected from the initial
dataset on the basis of fold-change (2-fold) and on
literature-documented expression during the im-
plantation window: (1) four genes previously descri-
bed in literature to be up-regulated during the
implantation window and selectively stimulated by
17b-E2+P in late proliferative phase but not men-
strual phase endometrium (Dickkopf homolog 1,
DDK1; thrombomodulin, THBD; monoamine ox-
idase A, MAOA; gastrin, GAS) [2, 20, 21]; (2) two
genes not yet reported that were selectively stimu-
lated by 17b-E2+P in late proliferative phase ex-
plants but not in menstrual phase explants (cytidine
deaminase, CDA; SPARC-like 1, SPARCL1); and
(3) two genes that were selectively stimulated by
17b-E2+P in menstrual phase explants but not in late
proliferative phase explants (trefoil factor 1, TFF1;
mammaglobin 1).
The real-time PCR results corroborated well with the
array data (Table 1). We performed additional inde-
pendent experiments to validate the observed effects
oftreatmentwith17b-E2+PandPalone(Fig. 1).From
the validated genes, DKK1, MAOA and SPARCL1
were significantly stimulated by P in late proliferative
andmenstrualphaseexplantsbothinthepresenceand
absence of 17b-E2. The induction of SPARCL1
expression by P was significantly decreased in the
presence of 17b-E2 in both menstrual and late
proliferative phase explants.
The response of DKK1 to P was higher in the late
proliferative phase explants than in the menstrual phase
explants, whereas the induction of mammaglobin expres-
sion by 17b-E2+P and P alone was more pronounced in
menstrual phase than in late proliferative phase endome-
trium. Thrombomodulin expression was induced only by
P in late proliferative phase explants.
The expression of DKK1, THBD, MAOA, GAS,
CDA and SPARCL1 was also assessed in an inde-
pendent series of ES and MS endometrial samples to
confirm selective up-regulation in the implantation
window. The expression levels are presented in Fig. 2.
The expression of DKK1, MAOA, CDA and
SPARCL1 was significantly higher in MS endome-
trium compared to ES endometrium.
Gene expression in menstrual and late proliferative
phaseendometrialtissueexplantsafter17b-E2+PorP
treatment. Treatment of late proliferative phase
endometrial tissue with 17b-E2+P up-regulated (2-
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regulated (2-fold) the expression of 109 gene tran-
scripts when compared to the control (vehicle)
(Table 2). Treating late proliferative phase explants
with P alone up-regulated (2-fold) the expression of
107genetranscriptsanddown-regulated(2-fold)the
expression of 54 gene transcripts when compared to
the control (vehicle) (Table 3). A total of 77/107 up-
regulated and 42/54 down-regulated genes were also
modulated by 17b-E2+P treatment in late prolifera-
tive phase explants (Table 3).
Theresponseofmenstrualphaseendometriumto17b-
E2+P was less pronounced than that of late prolifer-
ative phase endometrium. Treatment of menstrual
phase endometrial tissue with 17b-E2+P up-regulated
(2-fold) the expression of only 38 gene transcripts
and down-regulated (2-fold) the expression of 79
genetranscriptswhencomparedtothecontrolsample
(vehicle) (Table 4).
Almost all genes modulated by 17b-E2+P in late
proliferative phase endometrium were specific for
that phase of the cycle. Of the 110 up-regulated (2-
fold) gene transcripts, 100 were expressed in late
proliferative phase explants and not menstrual phase
explants; of these, 10 gene transcripts were docu-
mented to be up-regulated during the window of
implantation (Table 5). Of the 107 down-regulated
(2-fold) gene transcripts, 102 were selective for late
proliferative phase explants; of these, 7 genes were
documented to be down-regulated during the implan-
tation window (Table 5). The genes regulated by 17b-
E2+P in both menstrual and late proliferative phase
explants are presented in Table 6.
Ingenuity Pathways Analysis. Ingenuity Pathways
Analysis revealed various significant networks of
interconnected focus genes after treatment with 17b-
E2+P. In late proliferative phase endometrium, five
highlysignificantnetworkswereidentified.Network1
Table 1. Validation results of the microarray findings for selected genes.
Gene Real-time PCR individual samples Pooled array samples
E2+P M phase E2+P LP phase P alone M phase P alone LP phase E2+PE 2+P P alone
CD3 CD4 CD12 CD13 CD3 CD4 CD12 CD13 M phase LP phase LP phase
DKK1 1.80 1.93 2.67 12.68 3.20 2.96 4.27 13.69 1.58 6.03 5.01
THBD 1.11 1.14 2.72 4.08 2.24 3.59 2.67 3.48 1.30 2.95 2.43
MAOA 0.97 1.19 5.64 1.85 1.82 1.80 6.36 1.19 1.10 2.59 2.00
GAS 0.69 0.26 1.07 3.07 1.51 0.57 1.95 2.49 1.00 2.19 1.58
CDA 1.27 0.62 1.97 4.01 1.09 1.34 1.02 3.61 0.32 2.82 1.86
SPARCL1 1.47 2.43 6.96 3.02 1.11 1.87 4.07 2.36 1.29 2.00 2.04
Gene transcript levels of DKK1, THBD, MAOA, GAS, CDA and SPARCL1 were assessed with quantitative real-time PCR in the
individual samples used for microarray hybridization. Data are presented as fold change [P, progesterone; E2,1 7 b-oestradiol; CD, cycle
day; M, menstrual (n=2); LP, late proliferative (n=2)].
Figure 1. Mean fold changes
found for DKK1, THBD,
MAOA, GAS, CDA and
SPARCL1 in menstrual phase
(M, n=4) and late proliferative
phase (LP, n=3) explants treated
with 17b-oestradiol and proges-
terone (17b-E2+P, dark grey
bars) or P alone (light grey
bars). Controls (open bars) were
cultured with vehicle alone. Data
are presented as fold changes
(*p<0.05).
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MMP7, MMP9, SERPINE1 and EDN1; network 2
connected IL8, MMP14, FGF2, PDGFB, ITGB3,
PDGFRA, PDGFRB, PTGS2 and EGR1; network 3
related TGFb2, TGFb3, INHBA, PTHLH, JUN,
SMAD3 and SMAD7; network 4 linked IGF1,
TNFSF11 and HOXA9; and network 5 coupled
ICAM1, CXCL10, IL15, SOCS1, RARa and
ARNT2. Network 1 is illustrated in Figure 3.
Incontrast,inmenstrualphaseendometriumonlytwo
highly significant networks were extracted from the
data. One network connected CCL5, TNFS11,
INTGB3, MAPK8 and ESR1. The second network
linked IFGBP3, TGFb2, FGF2, HGF, PDGFA,
MMP9, PTGS2, RARb and EGR1. The latter net-
work is presented in Figure 2.
Discussion
Previous work in our laboratory has shown that
explant cultures of human endometrial tissue are
biologically relevant in vitro models to investigate
oestrogen regulation of gene expression and prolifer-
ation [12, 16]. With regard to progestins, it has been
shown that tissue cultures of human endometrium are
also responsive, as evidenced by the suppressive
effects on the production and activation of MMPs
[12–14].The present study was designed to gain more
insightintotheresponses ofhumanendometriumtoP
with regard to gene expression and the influence of
17b-E2. The results show that in explant cultures of
human endometrium, the expression of genes that
have been implicated in the process of embryo
implantation can be modulated by 17b-E2 and P.
Figure 2. Example of a highly significant network identified in the gene expression profile of menstrual phase endometrium treated with
17b-oestradiolandprogesterone(17b-E2+P)asdeterminedbytheIngenuityPathwaysAnalysisprogram.Greenindicatesdown-regulated
genes, and pink indicates up-regulated genes.
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Gene Gene Symbol fold
change
Accession # Function
cytochrome P450, family 26, subfamily A, polypeptide 1 CYP26A1 33.11 NM_000783.1 metabolism
hemoglobin, alpha 2 –- 28.18 V00489 –-
calpain 6 CAPN6 19.05 NM_014289.2 metabolism
heart and neural crest derivatives expressed 2 HAND2 10.47 NM_021973.1 transcription
factor
secretoglobin, family 1D, member 2 SCGB1D2 10.00 NM_006551.2 extracellular
matrix
hemoglobin, alpha 1 HBA1 9.55 AF105974.1 transport
FK506 binding protein 5 FKBP5 7.76 NM_004117.1 metabolism
chemokine (C-X-C motif) ligand 11 CXCL11 7.59 AF030514.1 signal
transduction
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 CHST7 7.08 NM_019886.1 metabolism
glycine-N-acyltransferase GLYAT 6.17 AW024233 metabolism
hemoglobin, beta HBB 6.17 M25079.1 transport
dickkopf homolog 1 (Xenopus laevis) DKK1 6.03 NM_012242.1 growth factor
Homo sapiens mutant beta-globin (HBB) gene, complete cds. –- 5.50 AF059180 –-
neuronal pentraxin II NPTX2 5.50 U26662.1 cell adhesion
PDZ domain containing 3 PDZK3 5.50 AF338650.1 signal
transduction
apolipoprotein D APOD 4.90 NM_001647.1 transport
alkaline phosphatase, placental (Regan isozyme) ALPP 4.79 NM_001632.2 metabolism
keratin 6A KRT6A 4.68 J00269.1 structural
protein
G protein-coupled receptor 105 GPR105 4.47 NM_014879.1 signal
transduction
solute carrier family 7, member 8 SLC7A8 4.37 NM_012244.1 transport
hypothetical protein FLJ11539 FLJ11539 4.17 NM_024748.1 –-
a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 8 ADAMTS8 3.98 NM_007037.1 cell growth
integrin, beta-like 1 ITGBL1 3.80 NM_004791.1 cell adhesion
potassium inwardly-rectifying channel, subfamily J, member 8 KCNJ8 3.80 NM_004982.1 transport
RGC32 protein RGC32 3.80 NM_014059.1 cell growth
prostaglandin-endoperoxide synthase 1 PTGS1 3.72 NM_000962.1 metabolism
regulator of G-protein signalling 2, 24kDa RGS2 3.72 NM_002923.1 signal
transduction
cannabinoid receptor 1 (brain) CNR1 3.55 U73304 signal
transduction
hemoglobin, delta HBD 3.39 NM_000519.2 transport
keratin 6B KRT6B 3.39 L42612.1 structural
protein
sushi-repeat-containing protein, X-linked SRPX 3.24 NM_006307.1 cell adhesion
thrombomodulin THBD 3.24 NM_000361.1 membrane
protein
delta sleep inducing peptide, immunoreactor DSIPI 3.16 AL110191.1 transcription
factor
cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1 3.09 J02871.1 metabolism
hemoglobin, gamma A HBG1 3.09 NM_000559.1 transport
paired basic amino acid cleaving system 4 PACE4 3.09 NM_002570.1 signal
transduction
insulin receptor substrate 2 IRS2 3.02 BF700086 signal
transduction
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Gene Gene Symbol fold
change
Accession # Function
metallothionein 1K MT1K 2.95 R06655 transport
amylase, alpha 1A; salivary AMY1A 2.88 NM_004038.1 metabolism
fibrinogen-like 2 FGL2 2.88 NM_006682.1 extracellular
matrix
latent transforming growth factor beta binding protein 1 LTBP1 2.88 NM_000627.1 protein binding
monoamine oxidase A MAOA 2.88 NM_000240.1 transport
retinol binding protein 4, plasma RBP4 2.88 NM_006744.2 transport
cytidine deaminase CDA 2.82 NM_001785.1 metabolism
potassium voltage-gated channel, subfamily G, member 1 KCNG1 2.82 AI332979 transport
mitogen-activated protein kinase kinase 6 MAP2K6 2.82 NM_002758.1 signal
transduction
solute carrier family 15 (H+/peptide transporter), member 2 SLC15A2 2.82 BF223679 transport
hemoglobin, gamma G HBG2 2.75 AI133353 transport
protein kinase, X-linked PRKX 2.75 NM_005044.1 metabolism
suppressor of cytokine signaling 1 SOCS1 2.75 AB005043.1 signal
transduction
KIAA0924 protein KIAA0924 2.69 NM_014897.1 nuclear
secretoglobin, family 1D, member 1 SCGB1D1 2.69 NM_006552.1 extracellular
matrix
serine (or cysteine) proteinase inhibitor, clade E, member 1 SERPINE1 2.69 NM_000602.1 metabolism
chloride channel 4 CLCN4 2.63 AA071195 transport
fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 2.63 NM_001995.1 metabolism
monoamine oxidase B MAOB 2.63 NM_000898.1 transport
secretoglobin, family 2A, member 1 SCGB2A1 2.63 NM_002407.1 hormone
binding
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A ATP6V1A 2.57 NM_001690.1 transport
dipeptidylpeptidase 4 DPP4 2.57 M80536.1 metabolism
nuclear factor I/B NFIB 2.57 AI186739 transcription
factor
creatine kinase, brain CKB 2.51 NM_001823.1 metabolism
cytokine receptor-like factor 1 CRLF1 2.51 NM_004750.1 signal
transduction
iroquois homeobox protein 4 IRX4 2.51 NM_016358.1 transcription
factor
Homo sapiens mRNA; cDNA DKFZp586B0220 –- 2.45 AL049435.1 –-
chemokine (C-X-C motif) ligand 10 CXCL10 2.45 NM_001565.1 signal
transduction
hypothetical protein FLJ20701 FLJ20701 2.45 NM_017933.1 –-
insulin-like growth factor binding protein 1 IGFBP1 2.45 NM_000596.1 signal
transduction
Norrie disease (pseudoglioma) NDP 2.45 NM_000266.1 signal
transduction
zinc finger protein 145 ZNF145 2.45 NM_006006.1 protein binding
hypothetical protein FLJ20366 FLJ20366 2.40 NM_017786.1 –-
peroxisome proliferative activated receptor, gamma, coactivator 1 PPARGC1 2.40 NM_013261.1 DNA binding
S100 calcium binding protein A2 S100A2 2.40 NM_005978.2 transport
Arg/Abl-interacting protein ArgBP2 ARGBP2 2.34 NM_021069.1 structural
protein
interleukin 1 receptor-like 1 IL1RL1 2.34 NM_003856.1 signal
transduction
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Gene Gene Symbol fold
change
Accession # Function
NPD009 protein NPD009 2.34 AF237813.1 –-
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal
domain, 2
CITED2 2.29 NM_006079.1 transcription
factor
colony stimulating factor 2 receptor, alpha, low-affinity CSF2RA 2.29 BC002635.1 immune
response
secreted and transmembrane 1 SECTM1 2.29 BF939675 membrane
protein
H.sapiens mRNA for interleukin-15 –- 2.24 Y09908.1 –-
GREB1 protein GREB1 2.24 NM_014668.1 –-
adiponectin receptor 2 ADIPOR2 2.19 NM_024551.1 membrane
protein
hypothetical protein DKFZp434B044 DKFZP434B044 2.19 AL136861.1 extracellular
matrix
gastrin GAS 2.19 NM_000805.2 signal
transduction
alkaline phosphatase, liver/bone/kidney ALPL 2.14 X14174.1 metabolism
chromosome 1 open reading frame 29 C1orf29 2.14 NM_006820.1 –-
Fas apoptotic inhibitory molecule FAIM 2.14 NM_018147.1 –-
KIAA0089 protein KIAA0089 2.14 AA135522 metabolism
POU domain, class 5, transcription factor 1 POU5F1 2.14 NM_002701.1 transcription
factor
serum amyloid A2 SAA2 2.14 M23699.1 immune
response
SEC14-like 1 (S. cerevisiae) SEC14L1 2.14 AV748469 transport
solute carrier family 26 (sulfate transporter), member 2 SLC26A2 2.14 AI025519 transport
CDC14 cell division cycle 14 homolog B (S. cerevisiae) CDC14B 2.09 AU145941 metabolism
hypothetical protein FLJ11795 FLJ11795 2.09 NM_024669.1 –-
likely ortholog of mouse tumor necrosis-alpha-induced adipose-related
protein
FLJ23153 2.09 NM_024636.1 transport
KIAA0960 protein KIAA0960 2.09 BF447246 –-
oxysterol binding protein-like 11 OSBPL11 2.09 NM_022776.1 transport
protein tyrosine phosphatase, receptor type, R PTPRR 2.09 NM_002849.1 signal
transduction
fibrinogen, A alpha polypeptide FGA 2.04 NM_021871.1 cell adhesion
interleukin 6 signal transducer (gp130, oncostatin M receptor) IL6ST 2.04 AB015706.1 signal
transduction
KIAA0367 protein KIAA0367 2.04 AL138349 –-
KIAA0711 gene product KIAA0711 2.04 NM_014867.1 protein binding
ADP-ribosyltransferase 3 ART3 2.00 U47054.1 metabolism
cut-like 2 (Drosophila) CUTL2 2.00 AB006631.1 transcription
factor
dual specificity phosphatase 1 DUSP1 2.00 AA530892 metabolism
eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa EIF2S3 2.00 NM_001415.1 translation
interleukin 20 receptor, alpha IL20RA 2.00 NM_014432.1 signal
transduction
PRO2000 protein PRO2000 2.00 NM_014109.1 DNA binding
solute carrier family 7, member 2 SLC7A2 2.00 NM_003046.1 transport
SPARC-like 1 (mast9, hevin) SPARCL1 2.00 NM_004684.1 –-
toll-like receptor 2 TLR2 2.00 NM_003264.1 immune
response
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coagulation factor XIII, A1 polypeptide F13A1 2.00 NM_000129.2 metabolism
protein kinase (cAMP-dependent, catalytic) inhibitor alpha PKIA 2.00 NM_006823.1 metabolism
glutaminyl-peptide cyclotransferase (glutaminyl cyclase) QPCT 2.00 NM_012413.2 metabolism
TGF2_HUMANTransforminggrowthfactorbeta2precursor(TGF-beta2) –- 2.04 BF061658 –-
cadherin 5, type 2, VE-cadherin (vascular epithelium) CDH5 2.04 NM_001795.1 cell adhesion
cellular retinoic acid binding protein 2 CRABP2 2.04 NM_001878.2 signal
transduction
drebrin 1 DBN1 2.04 NM_004395.1 structural
protein
dimethylarginine dimethylaminohydrolase 2 DDAH2 2.04 AJ012008 metabolism
early growth response 1 EGR1 2.04 NM_001964.1 transcription
factor
hypothetical protein FLJ11082 FLJ11082 2.04 NM_018317.1 –-
matrix metalloproteinase 1 (interstitial collagenase) MMP1 2.04 NM_002421.2 metabolism
matrix metalloproteinase 3 (stromelysin 1, progelatinase) MMP3 2.04 NM_002422.2 metabolism
matrix metalloproteinase 9 MMP9 2.04 NM_004994.1 metabolism
reticulon 3 RTN3 2.04 NM_023941.1 membrane
protein
stanniocalcin 1 STC1 2.04 U46768.1 signal
transduction
Thy-1 cell surface antigen THY1 2.04 AL558479 membrane
protein
tumor necrosis factor receptor superfamily, member 21 TNFRSF21 2.04 NM_016629.1 signal
transduction
basic helix-loop-helix domain containing, class B, 3 BHLHB3 2.09 BE857425 transcription
factor
chromosome 21 open reading frame 7 C21orf7 2.09 NM_020152.1 –-
glycoprotein A repetitions predominant GARP 2.09 NM_005512.1 –-
regulator of G-protein signalling 3 RGS3 2.09 NM_021106.1 signal
transduction
trefoil factor 1 TFF1 2.09 NM_003225.1 growth factor
ATP-binding cassette, sub-family A (ABC1), member 8 ABCA8 2.14 NM_007168.1 transport
hypothetical gene BC008967 BC008967 2.14 BE299456 –-
solute carrier family 14 (urea transporter), member 1 SLC14A1 2.14 NM_015865.1 transport
a disintegrin and metalloproteinase domain 12 (meltrin alpha) ADAM12 2.19 NM_003474.2 metabolism
aquaporin 3 AQP3 2.19 AB001325 transport
carcinoembryonic antigen-related cell adhesion molecule 6 CEACAM6 2.19 BC005008.1 signal
transduction
chloride channel, calcium activated, family member 4 CLCA4 2.19 NM_012128.2 transport
chloride intracellular channel 2 CLIC2 2.19 AI768628 transport
DVS27-related protein DVS27 2.19 AB024518.1 –-
hypothetical protein FLJ31737 FLJ31737 2.19 N91149 –-
fascin homolog 1, actin-bundling protein FSCN1 2.19 NM_003088.1 structural
protein
synuclein, alpha interacting protein (synphilin) SNCAIP 2.19 NM_005460.1 protein binding
embryonal Fyn-associated substrate EFS 2.24 NM_005864.1 cell adhesion
integral membrane protein 2C ITM2C 2.24 NM_030926.1 –-
keratin 23 (histone deacetylase inducible) KRT23 2.24 NM_015515.1 –-
matrix metalloproteinase 27 MMP27 2.24 NM_022122.1 metabolism
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pre-B-cell leukemia transcription factor 1 PBX1 2.24 BF967998 transcription
factor
suppression of tumorigenicity ST7 2.24 NM_013437.1 –-
Homo sapiens mRNA, chromosome 1 specific transcript KIAA0509. –- 2.29 AB007978.1 –-
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B APOBEC3B 2.29 NM_004900.1 metabolism
ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology domains-
containing protein 3
ARAP3 2.29 NM_022481.1 signal
transduction
carboxypeptidase Z CPZ 2.29 BC006393.1 metabolism
melanoma antigen, family D, 4 MAGED4 2.29 NM_030801.1 –-
matrilin 4 MATN4 2.29 NM_003833.2 extracellular
matrix
regulator of G-protein signalling 4 RGS4 2.29 AL514445 signal
transduction
chromosome 6 open reading frame 59 C6orf59 2.34 NM_020133.1 –-
aldo-keto reductase family 1, member B10 (aldose reductase) AKR1B10 2.40 NM_020299.1 metabolism
angiopoietin 2 ANGPT2 2.40 AF187858.1 signal
transduction
dapper homolog 1, antagonist of beta-catenin (xenopus) DACT1 2.40 NM_016651.2 nuclear
G protein-coupled receptor 17 GPR17 2.40 NM_005291.1 signal
transduction
glutathione peroxidase 2 (gastrointestinal) GPX2 2.40 NM_002083.1 metabolism
microfibrillar-associated protein 2 MFAP2 2.40 NM_017459.1 extracellular
matrix
transforming growth factor, beta 3 TGFB3 2.40 J03241.1 growth factor
WNT1 inducible signaling pathway protein 2 WISP2 2.40 NM_003881.1 signal
transduction
hepatocyte growth factor (hepapoietin A; scatter factor) HGF 2.45 M77227.1 growth factor
KIAA1277 protein KIAA1277 2.45 AA127623 –-
matrix metalloproteinase 14 (membrane-inserted) MMP14 2.45 AU149305 metabolism
Ras family member Ris RIS 2.45 NM_016563.1 signal
transduction
thymosin, beta, identified in neuroblastoma cells TMSNB 2.45 NM_021992.1 structural
protein
latexin protein LXN 2.51 NM_020169.1 –-
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 SERPINB2 2.51 NM_002575.1 cell growth
carbonic anhydrase II CA2 2.57 M36532.1 metabolism
deleted in malignant brain tumors 1 DMBT1 2.57 NM_004406.1 cell growth
fibronectin leucine rich transmembrane protein 2 FLRT2 2.57 NM_013231.1 cell adhesion
orosomucoid 1 ORM1 2.57 NM_000608.1 transport
stathmin-like 2 STMN2 2.57 BF967657 signal
transduction
synaptojanin 2 SYNJ2 2.57 AF318616.1 metabolism
carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 2.63 NM_004363.1 membrane
protein
ectodermal-neural cortex (with BTB-like domain) ENC1 2.63 NM_003633.1 protein binding
mucin 4, tracheobronchial MUC4 2.63 AJ242547.1 signal
transduction
protocadherin 16 dachsous-like (Drosophila) PCDH16 2.63 BF222893 cell adhesion
interleukin 24 IL24 2.69 NM_006850.1 signal
transduction
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transforming growth factor, beta 2 TGFB2 2.69 NM_003238.1 growth factor
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 2.75 M35999.1 cell adhesion
plasminogen activator, urokinase PLAU 2.75 NM_002658.1 metabolism
chromosome 20 open reading frame 42 C20orf42 2.82 NM_017671.1 –-
four jointed box 1 (Drosophila) FJX1 2.82 NM_014344.1 –-
ephrin-B2 EFNB2 2.88 BF001670 cell growth
parathyroid hormone-like hormone PTHLH 2.88 BC005961.1 signal
transduction
tribbles homolog 2 TRB2 2.88 NM_021643.1 metabolism
twist homolog 1 TWIST1 2.88 X99268.1 DNA binding
gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2.95 NM_002060.1 transport
integrin, beta 6 ITGB6 2.95 NM_000888.3 cell adhesion
bradykinin receptor B1 BDKRB1 3.02 NM_000710.1 signal
transduction
solute carrier family 21 (organic anion transporter), member 11 SLC21A11 3.02 NM_013272.2 transport
myristoylated alanine-rich protein kinase C substrate MARCKS 3.09 M68956.1 membrane
protein
angiopoietin-like 2 ANGPTL2 3.16 NM_012098.1 signal
transduction
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) TNFRSF11B 3.16 NM_002546.1 signal
transduction
acid phosphatase, prostate ACPP 3.24 NM_001099.2 metabolism
homeo box A11 HOXA11 3.24 NM_005523.3 transcription
factor
hypothetical protein FLJ38993 FLJ38993 3.31 AF070524.1 signal
transduction
matrix metalloproteinase 11 (stromelysin 3) MMP11 3.31 AI761713 metabolism
pleckstrin 2 PLEK2 3.31 NM_016445.1 signal
transduction
SRY (sex determining region Y)-box 9 SOX9 3.31 NM_000346.1 DNA binding
lymphocyte-specific protein tyrosine kinase LCK 3.39 NM_005356.1 signal
transduction
BDG-29 proten BDG29 3.47 AL117532.1 DNA binding
deiodinase, iodothyronine, type II DIO2 3.47 U53506.1 metabolism
SRY (sex determining region Y)-box 4 SOX4 3.47 AI989477 transcription
factor
cysteine knot superfamily 1, BMP antagonist 1 CKTSF1B1 3.63 AF154054.1 –-
chromogranin A (parathyroid secretory protein 1) CHGA 3.72 NM_001275.2 transport
cystic fibrosis transmembrane conductance regulator, ATP-bindingcassette CFTR 4.07 NM_000492.2 transport
Ras-induced senescence 1 RIS1 4.07 BF062629 –-
hypothetical protein FLJ10640 FLJ10640 4.17 NM_024703.1 metabolism
ribosomal protein S20 RPS20 4.27 AF113008.1 protein
biosynthesis
SRY (sex determining region Y)-box 11 SOX11 4.68 AB028641.1 transcription
factor
platelet-derived growth factor beta polypeptide PDGFB 5.75 NM_002608.1 growth factor
ribosomal protein L27a RPL27A 5.75 BE737027 protein
biosynthesis
Genetranscriptsregulated(2-fold)by17b-E2+Pinlateproliferativephaseexplantswhencomparedtothevehicle-treatedcontrols.Data
are presented as fold changes.
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cytochrome P450, family 26, subfamily A, polypeptide 1 CYP26A1 28.84 NM_000783.1 metabolism
calpain 6 CAPN6 19.50 NM_014289.2 metabolism
hemoglobin, alpha 2 –- 12.88 V00489 –-
heart and neural crest derivatives expressed 2 HAND2 10.96 NM_021973.1 transcription
factor
secretoglobin, family 1D, member 2 SCGB1D2 9.55 NM_006551.2 extracellular
matrix
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 CHST7 7.59 NM_019886.1 metabolism
glycine-N-acyltransferase GLYAT 7.08 AW024233 metabolism
FK506 binding protein 5 FKBP5 6.31 NM_004117.1 metabolism
PDZ domain containing 3 PDZK3 6.17 AF338650.1 signal
transduction
neuronal pentraxin II NPTX2 6.03 U26662.1 cell adhesion
chemokine (C-X-C motif) ligand 11 CXCL11 5.50 AF030514.1 signal
transduction
solute carrier family 7, member 8 SLC7A8 5.25 NM_012244.1 transport
a disintegrin-like and metalloprotease with thrombospondin type 1
motif, 8
ADAMTS8 5.01 NM_007037.1 metabolism
dickkopf homolog 1 (Xenopus laevis) DKK1 5.01 NM_012242.1 growth factor
keratin 6A KRT6A 4.90 J00269.1 structural protein
alkaline phosphatase, placental (Regan isozyme) ALPP 4.79 NM_001632.2 metabolism
apolipoprotein D APOD 4.68 NM_001647.1 transport
G protein-coupled receptor 105 GPR105 4.68 NM_014879.1 signal
transduction
prostaglandin-endoperoxide synthase 1 PTGS1 4.68 NM_000962.1 metabolism
TU3A protein TU3A 4.68 AL050264.1 –-
hemoglobin, alpha 1 HBA1 4.57 AF105974.1 transport
mitogen-activated protein kinase kinase 6 MAP2K6 4.27 NM_002758.1 signal
transduction
keratin 6B KRT6B 4.07 L42612.1 structural protein
claudin 5 CLDN5 3.98 NM_003277.1 structural protein
regulator of G-protein signalling 2, 24kDa RGS2 3.98 NM_002923.1 signal
transduction
RGC32 protein RGC32 3.89 NM_014059.1 cell growth
integrin, beta-like 1 ITGBL1 3.80 NM_004791.1 cell adhesion
solute carrier family 15, member 2 SLC15A2 3.72 BF223679 transport
delta sleep inducing peptide, immunoreactor DSIPI 3.55 AL110191.1 transcription
factor
myosin heavy chain Myr 8 MYR8 3.55 AI522028 metabolism
potassium inwardly-rectifying channel, subfamily J, member 8 KCNJ8 3.31 NM_004982.1 transport
paired basic amino acid cleaving system 4 PACE4 3.31 NM_002570.1 signal
transduction
cannabinoid receptor 1 (brain) CNR1 3.24 U73304 signal
transduction
hypothetical protein FLJ11539 FLJ11539 3.24 NM_024748.1 –-
protein kinase, X-linked PRKX 3.24 NM_005044.1 metabolism
latent transforming growth factor beta binding protein 1 LTBP1 3.16 NM_000627.1 protein binding
KIAA0960 protein KIAA0960 3.09 BF447246 –-
nuclear factor I/B NFIB 3.02 AI186739 transcription
factor
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sushi-repeat-containing protein, X-linked SRPX 3.02 NM_006307.1 cell adhesion
cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1 2.95 J02871.1 metabolism
insulin receptor substrate 2 IRS2 2.95 BF700086 signal
transduction
potassium voltage-gated channel, subfamily G, member 1 KCNG1 2.95 AI332979 transport
Arg/Abl-interacting protein ArgBP2 ARGBP2 2.88 NM_021069.1 structural protein
hemoglobin, beta HBB 2.88 M25079.1 transport
Homo sapiens mutant beta-globin (HBB) gene, complete cds. –- 2.82 AF059180 –-
RAR-related orphan receptor B RORB 2.82 NM_006914.1 transcription
factor
S100 calcium binding protein A2 S100A2 2.75 NM_005978.2 transport
serum amyloid A2 SAA2 2.75 NM_030754.1 immune response
absent in melanoma 1-like AIM1L 2.69 NM_017977.1 –-
RIM binding protein 2 KIAA0318 2.69 AB002316.1 transport
thrombomodulin THBD 2.69 NM_000361.1 signal
transduction
cytokine receptor-like factor 1 CRLF1 2.63 NM_004750.1 signal
transduction
v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) MAF 2.51 NM_005360.2 transcription
factor
monoamine oxidase B MAOB 2.51 NM_000898.1 transport
secretoglobin, family 1D, member 1 SCGB1D1 2.51 NM_006552.1 extracellular
matrix
interleukin 15 IL15 2.45 NM_000585.1 signal
transduction
hypothetical protein FLJ20701 FLJ20701 2.45 NM_017933.1 –-
secretoglobin, family 2A, member 1 SCGB2A1 2.45 NM_002407.1 hormone binding
dipeptidylpeptidase 4 DPP4 2.40 M80536.1 metabolism
immunoglobulin kappa constant IGKC 2.40 BC005332.1 immune response
immunoglobulin heavy constant gamma 3 (G3 m marker) IGHG3 2.34 M87789.1 immune response
iroquois homeobox protein 4 IRX4 2.34 NM_016358.1 transcription
factor
killer cell immunoglobulin-like receptor, two domains, short
cytoplasmic tail, 1
KIR2DS1 2.34 NM_014512.1 immune response
metallothionein 1K MT1K 2.34 R06655 transport
amylase, alpha 1A; salivary AMY1A 2.29 NM_004038.1 metabolism
creatine kinase, brain CKB 2.29 NM_001823.1 metabolism
cut-like 2 (Drosophila) CUTL2 2.29 AB006631.1 transcription
factor
fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 2.29 NM_001995.1 metabolism
PRO2000 protein PRO2000 2.29 NM_014109.1 DNA binding
serine (or cysteine) proteinase inhibitor, clade E , member 1 SERPINE1 2.29 NM_000602.1 metabolism
adiponectin receptor 2 ADIPOR2 2.24 NM_024551.1 membrane
protein
alkaline phosphatase, liver/bone/kidney ALPL 2.24 X14174.1 metabolism
N-acylsphingosine amidohydrolase (acid ceramidase)-like ASAHL 2.24 AK024677.1 metabolism
hypothetical protein FLJ20366 FLJ20366 2.24 NM_017786.1 –-
Norrie disease (pseudoglioma) NDP 2.24 NM_000266.1 signal
transduction
zinc finger, BED domain containing 2 ZBED2 2.24 NM_024508.1 DNA binding
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zinc finger protein 145 ZNF145 2.24 NM_006006.1 protein binding
Fas apoptotic inhibitory molecule FAIM 2.19 NM_018147.1 –-
insulin-like growth factor binding protein 1 IGFBP1 2.19 NM_000596.1 signal
transduction
interleukin 20 receptor, alpha IL20RA 2.19 NM_014432.1 signal
transduction
mesothelin MSLN 2.19 NM_005823.2 –-
secreted and transmembrane 1 SECTM1 2.19 BF939675 membrane
protein
CDC14 cell division cycle 14 homolog B CDC14B 2.14 AU145941 metabolism
cathepsin E CTSE 2.14 NM_001910.1 metabolism
LIM and cysteine-rich domains 1 LMCD1 2.14 NM_014583.1 –-
monoamine oxidase A MAOA 2.14 NM_000240.1 transport
toll-like receptor 2 TLR2 2.14 NM_003264.1 signal
transduction
Homo sapiens mRNA; cDNA DKFZp586B0220 –- 2.09 AL049435.1 –-
hypothetical protein DKFZp434B044 DKFZP434B044 2.09 AL136861.1 extracellular
matrix
glutamyl aminopeptidase ENPEP 2.09 L12468.1 metabolism
epithelial V-like antigen 1 EVA1 2.09 NM_005797.1 cell adhesion
fibulin 2 FBLN2 2.09 NM_001998.1 extracellular
matrix
KIAA0924 protein KIAA0924 2.09 NM_014897.1 nuclear
KIAA1609 protein KIAA1609 2.09 AA195017 –-
neuroligin 4 NLGN4 2.09 AI338338 cell adhesion
peroxisome proliferative activated receptor, gamma, coactivator 1 PPARGC1 2.09 NM_013261.1 DNA binding
solute carrier family 26, member 2 SLC26A2 2.09 AI025519 transport
CDC42 effector protein 3 CDC42EP3 2.04 AI754416 –-
GREB1 protein GREB1 2.04 NM_014668.1 –-
interleukin 1 receptor-like 1 IL1RL1 2.04 NM_003856.1 signal
transduction
leucine-rich repeat-containing 1 LRRC1 2.04 NM_018214.1 –-
protein kinase, AMP-activated, gamma 2 non-catalytic subunit PRKAG2 2.04 NM_016203.1 metabolism
SPARC-like 1 (mast9, hevin) SPARCL1 2.04 NM_004684.1 –-
chromosome 18 open reading frame 1 C18orf1 2.00 NM_004338.1 membrane
protein
choline phosphotransferase 1 CHPT1 2.00 AF195624.1 metabolism
endothelial differentiation, lysophosphatidic acid G-protein-coupled
receptor, 7
EDG7 2.00 NM_012152.1 signal
transduction
retinol binding protein 4, plasma RBP4 2.00 NM_006744.2 transport
carcinoembryonic antigen-related cell adhesion molecule 5 CEACAM5 2.00 NM_004363.1 membrane
protein
chromosome condensation 1 CHC1 2.00 NM_001269.1 cell growth
cytochrome P450, family 27, subfamily B, polypeptide 1 CYP27B1 2.00 NM_000785.1 metabolism
DVS27-related protein DVS27 2.00 AB024518.1 –-
four jointed box 1 (Drosophila) FJX1 2.00 NM_014344.1 –-
interleukin 24 IL24 2.00 NM_006850.1 cell growth
matrix metalloproteinase 11 (stromelysin 3) MMP11 2.00 AI761713 metabolism
synaptojanin 2 SYNJ2 2.00 AF318616.1 metabolism
aldo-keto reductase family 1, member B10 (aldose reductase) AKR1B10 2.04 NM_020299.1 metabolism
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neuromedin B NMB 2.04 NM_021077.1 signal
transduction
pleckstrin 2 PLEK2 2.04 NM_016445.1 structural protein
transmembrane protease, serine 3 TMPRSS3 2.04 NM_024022.1 metabolism
twist homolog 1 TWIST1 2.04 X99268.1 DNA binding
hypothetical protein FLJ38993 FLJ38993 2.09 AF070524.1 signal
transduction
somatostatin SST 2.09 NM_001048.1 signal
transduction
chromosome 21 open reading frame 7 C21orf7 2.14 NM_020152.1 –-
carboxypeptidase M CPM 2.14 NM_001874.1 metabolism
glutathione peroxidase 2 (gastrointestinal) GPX2 2.14 NM_002083.1 metabolism
orosomucoid 1 ORM1 2.14 NM_000607.1 transport
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member
2
SERPINB2 2.14 NM_002575.1 cell growth
solute carrier family 14 (urea transporter), member 1 SLC14A1 2.14 NM_015865.1 transport
SRY (sex determining region Y)-box 4 SOX4 2.14 AI989477 transcription
factor
tribbles homolog 2 TRB2 2.14 NM_021643.1 metabolism
chromosome 20 open reading frame 42 C20orf42 2.19 NM_017671.1 –-
dapper homolog 1, antagonist of beta-catenin (xenopus) DACT1 2.19 NM_016651.2 nuclear
ectodermal-neural cortex ENC1 2.24 AF010314.1 protein binding
keratin 23 KRT23 2.24 NM_015515.1 –-
deiodinase, iodothyronine, type II DIO2 2.29 U53506.1 metabolism
plasminogen activator, urokinase PLAU 2.29 NM_002658.1 metabolism
NY-REN-7 antigen NY-REN-7 2.34 AL117630.1 –-
stanniocalcin 1 STC1 2.40 U46768.1 signal
transduction
carbonic anhydrase II CA2 2.45 M36532.1 metabolism
G protein-coupled receptor 17 GPR17 2.45 NM_005291.1 signal
transduction
high mobility group AT-hook 1 HMGA1 2.45 AF176039.1 transcription
factor
Ras-induced senescence 1 RIS1 2.45 BF062629 –-
trefoil factor 1 TFF1 2.45 NM_003225.1 growth factor
WNT1 inducible signaling pathway protein 2 WISP2 2.45 NM_003881.1 signal
transduction
aquaporin 3 AQP3 2.51 AB001325 transport
SRY (sex determining region Y)-box 9 SOX9 2.51 NM_000346.1 transcription
factor
bradykinin receptor B1 BDKRB1 2.57 NM_000710.1 signal
transduction
ephrin-B2 EFNB2 2.57 U16797.1 signal
transduction
gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2.57 NM_002060.1 transport
myristoylated alanine-rich protein kinase C substrate MARCKS 2.88 AW163148 structural protein
tumor necrosis factor receptor superfamily, member 11b
(osteoprotegerin)
TNFRSF11B 2.88 NM_002546.1 signal
transduction
small proline-rich protein 2B SPRR2B 2.95 NM_006945.1 structural protein
chromogranin A (parathyroid secretory protein 1) CHGA 3.02 NM_001275.2 transport
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Homo sapiens non-functional folate binding protein (HSAF000381),
mRNA
–- 3.16 NM_013307.1 –-
acid phosphatase, prostate ACPP 3.31 NM_001099.2 metabolism
integrin, beta 3 ITGB3 3.47 M35999.1 cell adhesion
platelet-derived growth factor beta polypeptide PDGFB 3.47 NM_002608.1 growth factor
SRY (sex determining region Y)-box 11 SOX11 3.72 AB028641.1 transcription
factor
cysteine knot superfamily 1, BMP antagonist 1 CKTSF1B1 3.89 AF154054.1 –-
ribosomal protein S20 RPS20 6.17 AF113008.1 protein
biosynthesis
ribosomal protein L27a RPL27A 7.59 BE737027 protein
biosynthesis
Gene transcripts regulated (2-fold) by progesterone alone in late proliferative phase explants when compared to the vehicle-treated
controls. Data are presentedas fold changes. The genes in bold were not found to be modulated by 17b-oestradiol and progesterone (17b-
E2+P).
Figure 3. Exampleofahighlysignificantnetworkidentifiedinthegeneexpressionprofileoflateproliferativephaseendometriumtreated
with 17b-oestradiol and progesterone (17b-E2+P) as determined by the Ingenuity Pathways Analysis program. Green indicates down-
regulated genes, and pink indicates up-regulated genes.
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Gene GeneSymbol fold change Accession # function
secretoglobin, family 1D, member 2 SCGB1D2 60.26 NM_006551.2 extracellular
matrix
alkaline phosphatase, placental (Regan isozyme) ALPP 10.00 NM_001632.2 metabolism
hypothetical protein FLJ10847 FLJ10847 7.08 NM_018242.1 transport
secretoglobin, family 2A, member 1 SCGB2A1 6.92 NM_002407.1 hormone binding
secretoglobin, family 2A, member 2 SCGB2A2 6.03 NM_002411.1 hormone binding
trefoil factor 1 TFF1 5.13 NM_003225.1 growth factor
cytochrome P450, family 26, subfamily A, polypeptide 1 CYP26A1 4.68 NM_000783.1 transport
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 CHST7 4.57 NM_019886.1 metabolism
hypothetical protein FLJ10640 FLJ10640 3.47 NM_024703.1 metabolism
hydroxysteroid (17-beta) dehydrogenase 2 HSD17B2 3.39 NM_002153.1 metabolism
paired box gene 5 (B-cell lineage specific activator protein) PAX5 3.31 NM_016734.1 transcription
factor
apolipoprotein D APOD 3.09 NM_001647.1 transport
solute carrier family 7 (cationic amino acid transporter, y+ system),
member 8
SLC7A8 2.75 NM_012244.1 transport
DNA segment on chromosome 4 (unique) 234 expressed sequence D4S234E 2.69 NM_014392.1 nuclear
GREB1 protein GREB1 2.69 NM_014668.1 –-
anthrax toxin receptor 1 ANTXR1 2.63 NM_018153.1 membrane
protein
histone 1, H2bd HIST1H2BD 2.63 AL353759 DNA binding
prostaglandin-endoperoxide synthase 2 PTGS2 2.63 NM_000963.1 metabolism
heat shock 70kDa protein 6 (HSP70B ) HSPA6 2.57 NM_002155.1 metabolism
cyclin A1 CCNA1 2.45 NM_003914.1 cell growth
asparaginase like 1 ASRGL1 2.40 NM_025080.1 metabolism
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B APOBEC3B 2.34 NM_004900.1 metabolism
hypothetical protein FLJ20152 FLJ20152 2.34 AI816291 –-
histone 1, H2bh HIST1H2BH 2.34 NM_003524.1 DNA binding
Homo sapiens mRNA; cDNA DKFZp564G112 –- 2.24 AA053967 –-
crystallin, alpha B CRYAB 2.19 AF007162.1 structural protein
colony stimulating factor 3 (granulocyte) CSF3 2.19 NM_000759.1 signal
transduction
histone 1, H1c HIST1H1C 2.19 BC002649.1 DNA binding
insulin-like growth factor binding protein 1 IGFBP1 2.19 NM_000596.1 signal
transduction
serine (or cysteine) proteinase inhibitor, clade A, member 3 SERPINA3 2.19 NM_001085.2 immune respons
apolipoprotein M APOM 2.14 NM_019101.1 transport
piggyBac transposable element derived 5 PGBD5 2.14 NM_024554.1 –-
trefoil factor 3 (intestinal) TFF3 2.14 NM_003226.1 immune respons
histone 1, H2bi HIST1H2BI 2.04 NM_003525.1 DNA binding
H2B histone family, member S H2BFS 2.00 NM_017445.1 DNA binding
putative chemokine receptor HM74 2.00 NM_006018.1 signal
transduction
metallothionein 1X MT1X 2.00 NM_002450.1 transport
TUWD12 TUWD12 2.00 NM_003774.2 –-
hyaluronan binding protein 2 HABP2 2.00 NM_004132.1 metabolism
interleukin 2 receptor, beta IL2RB 2.00 NM_000878.1 immune respons
myosin, light polypeptide kinase MYLK 2.00 NM_005965.1 signal
transduction
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SAM and SH3 domain containing 1 SASH1 2.00 AK025495.1 cell growth
transglutaminase 2 TGM2 2.00 BC003551.1 metabolism
adipose specific 2 APM2 2.04 NM_006829.1 –-
Microfibril-associated glycoprotein-2 MAGP2 2.04 AW665892 extracellular
matrix
3-phosphoinositide dependent protein kinase-1 PDPK1 2.04 NM_002613.1 signal
transduction
polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa POLR2J 2.04 AI738591 DNA binding
preferentially expressed antigen in melanoma PRAME 2.04 NM_006115.1 –-
transmembrane protein 5 TMEM5 2.04 BF224146 membrane
protein
leucine-rich repeat-containing 5 LRRC5 2.09 NM_018103.1 –-
parathyroid hormone receptor 2 PTHR2 2.09 NM_005048.1 signal
transduction
retinoblastoma binding protein 6 RBBP6 2.09 NM_006910.1 cell growth
cadherin 6, type 2, K-cadherin (fetal kidney) CDH6 2.14 AU151483 cell adhesion
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
(avian)
MYCN 2.14 BC002712.1 transcription
factor
SRY (sex determining region Y)-box 4 SOX4 2.14 AI989477 transcription
factor
zinc finger, BED domain containing 2 ZBED2 2.14 NM_024508.1 DNA binding
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ABCC3 2.19 AF009670.1 transport
hypothetical protein LOC339290 LOC339290 2.19 H49382 –-
hypothetical protein MGC29643 MGC29643 2.19 AL567376 –-
transcription factor 4 TCF4 2.19 AU118026 transcription
factor
nudix (nucleoside diphosphate linked moiety X)-type motif 6 NUDT6 2.24 NM_007083.1 growth factor
ribosomal protein S6 kinase, 90kDa, polypeptide 5 RPS6KA5 2.24 AF074393.1 metabolism
heme oxygenase (decycling) 1 HMOX1 2.29 NM_002133.1 metabolism
killer cell lectin-like receptor subfamily B, member 1 KLRB1 2.29 NM_002258.1 signal
transduction
PTPRF interacting protein, binding protein 2 (liprin beta 2) PPFIBP2 2.29 AI692180 DNA binding
ubiquitin D UBD 2.29 NM_006398.1 –-
laminin, alpha 3 LAMA3 2.34 NM_000227.1 structural protein
ribonucleotide reductase M2 polypeptide RRM2 2.34 BE966236 metabolism
Rho guanine nucleotide exchange factor (GEF) 17 ARHGEF17 2.40 NM_014786.1 –-
N-myristoyltransferase 1 NMT1 2.40 AI570834 metabolism
Homo sapiens cDNA: FLJ22812 fis, clone KAIA2955 –- 2.45 AK026465.1 –-
solute carrier family 16 (monocarboxylic acid transporters), member 6 SLC16A6 2.45 NM_004694.1 transport
spondin 1, (f-spondin) extracellular matrix protein SPON1 2.45 AI885290 extracellular
matrix
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s
(factor B)
ATP5S 2.51 NM_015684.1 –-
chemokine (C-C motif) ligand 5 CCL5 2.51 M21121 signal
transduction
CD96 antigen CD96 2.51 NM_005816.1 cell adhesion
growth associated protein 43 GAP43 2.51 NM_002045.1 cell growth
histone H2A.F/Z variant H2AV 2.51 BF343852 DNA binding
tumor necrosis factor receptor superfamily, member 4 TNFRSF4 2.51 AJ277151 immune respons
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chemokine (C motif) ligand 1 XCL1 2.57 U23772.1 signal
transduction
Homo sapiens transcribed sequences –- 2.63 BE045982 –-
C-terminal binding protein 1 CTBP1 2.63 AA053830 metabolism
fibroblast growth factor 9 (glia-activating factor) FGF9 2.63 NM_002010.1 growth factor
latexin protein LXN 2.63 NM_020169.1 –-
protocadherin gamma subfamily C, 3 PCDHGC3 2.63 AB002325.1 transport
cathepsin W (lymphopain) CTSW 2.75 NM_001335.1 metabolism
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 DYRK2 2.75 NM_006482.1 metabolism
integrin, beta 6 ITGB6 2.75 NM_000888.3 signal
transduction
hypothetical protein LOC284266 LOC284266 2.75 AK025833.1 –-
platelet-derived growth factor alpha polypeptide PDGFA 2.75 X03795.1 growth factor
chromosome 14 open reading frame 117 C14orf117 2.82 NM_018678.1 –-
chromosome 20 open reading frame 42 C20orf42 2.82 NM_017671.1 –-
insulin-like growth factor binding protein 3 IGFBP3 2.82 BF340228 signal
transduction
chloride intracellular channel 3 CLIC3 2.88 NM_004669.1 signal
transduction
hypothetical protein FLJ11082 FLJ11082 2.88 NM_018317.1 –-
glutathione S-transferase theta 1 GSTT1 2.88 NM_000853.1 metabolism
B/K protein LOC51760 2.95 NM_016524.1 transport
retinoic acid receptor responder (tazarotene induced) 1 RARRES1 2.95 AI669229 cell growth
Homo sapiens, clone IMAGE:4866926, mRNA –- 3.09 AA631242 –-
chemokine (C-X-C motif) ligand 14 CXCL14 3.09 NM_004887.1 signal
transduction
chemokine (C motif) ligand 2 XCL2 3.09 NM_003175.1 signal
transduction
cytidine deaminase CDA 3.16 NM_001785.1 metabolism
erythrocyte membrane protein band 4.1 like 4A EPB41L4A 3.39 NM_022140.1 structural protein
zinc finger protein 426 ZNF426 3.39 NM_024106.1 transcription
factor
regulator of G-protein signalling 5 RGS5 3.63 AI183997 signal
transduction
KIAA0924 protein KIAA0924 3.72 NM_014897.1 nuclear
serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5 SERPINB5 4.07 NM_002639.1 cell adhesion
killer cell lectin-like receptor subfamily C, member 3 KLRC3 4.17 NM_002260.2 immune response
calcium channel, voltage-dependent, alpha 1G subunit CACNA1G 4.27 NM_018896.1 transport
protein phosphatase 1, regulatory (inhibitor) subunit 16B PPP1R16B 4.47 AB020630 signal
transduction
Homo sapiens mRNA; cDNA DKFZp564N1116 –- 4.68 BF344237 –-
integral membrane protein 2A ITM2A 4.79 NM_004867.1 membrane
protein
phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) PFAS 4.90 AL044326 metabolism
major histocompatibility complex, class II, DR beta 3 HLA-DRB3 5.13 BC005312.1 immune response
immunoglobulin lambda joining 3 IGLJ3 5.62 X57812.1 –-
fibroblast growth factor 18 FGF18 6.92 BC006245.1 growth factor
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cystic fibrosis transmembrane conductance regulator, ATP-binding
cassette
CFTR 8.32 NM_000492.2 transport
Gene transcripts regulated (2-fold) by 17b-E2+P in menstrual phase explants when compared to vehicle-treated controls. Data are
presented as fold changes.
Table 5. Genes affected by 17b-E2+P and reported to be altered in the implantation window.






dickkopf homolog 1 DKK1 6.03 NM_012242.1 12.1 7 12.6
thrombomodulin THBD 3.24 NM_000361.1 10
fibrinogen-like 2 FGL2 2.88 NM_006682.1 5
monoamine oxidase A MAOA 2.88 NM_000240.1 7.5 15
retinol binding protein 4, plasma RBP4 2.88 NM_006744.2 6
dipeptidylpeptidase 4 DPP4 2.57 M80536.1 15
nuclear factor I/B NFIB 2.57 AI186739 10
H.sapiens mRNA for interleukin-15 –- 2.24 Y09908.1 3.7 3 2.2
gastrin GAS 2.19 NM_000805.2 11
KIAA0367 protein KIAA0367 2.04 AL138349 4
coagulation factor XIII, A1 polypeptide F13A1 2.00 NM_000129.2 4.1
microfibrillar-associated protein 2 MFAP2 2.40 NM_017459.1 3
transforming growth factor, beta 3 TGFB3 2.40 J03241.1 2.44
gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 2.95 NM_002060.1 20
myristoylated alanine-rich protein kinase C substrate MARCKS 3.09 M68956.1 2.2
matrix metalloproteinase 11 (stromelysin 3) MMP11 3.31 AI761713 10
deiodinase, iodothyronine, type II DIO2 3.47 U53506.1 2.4
Genetranscriptsregulated(2-fold)by17b-oestradiolandprogesterone(17b-E2+P)thathavealsobeenreportedtobealteredduringthe
window of implantation (by Riesewijk et al. [2], Carson et al. [20] and Kao et al [21]).
Figure 4. Relative expression levels of gene transcripts for DKK1, THBD, MAOA, GAS, CDA and SPARCL1 in early secretory (n=7)
and mid-secretory (n=8) endometrium, which represent endometrial tissues exposed to low (pre-implantation window) and high
(implantation window) progesterone concentrations, respectively (*p<0.05).
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proliferative phase explants was almost twice the
number regulated in menstrual phase explants, indi-
cating that oestrogen priming sensitizes the endome-
trium for P regulation, most likely by induction of P
receptor gene expression [16]. In addition, most of
these genes were specifically modulated in the late
proliferative phase endometrium. Of these genes
(n=100), at least 17 were previously described to be
regulated in the implantation window (Table 5) [2, 20,
21].ThreeexamplesofsuchgenesareDKK1,MAOA
and SPARCL1. Regulation of expression by 17b-
E2+P and P alone was confirmed with real-time PCR
in both explant cultures and endometrium biopsy
specimens collected during the implantation window
and ES phase. These findings demonstrate that the
expression of genes associated with the implantation
window can be modulated in explant cultures of
human endometrium and that for most of these genes,
prolonged in vivo exposure to 17b-E2 is required for
adequatePregulation.Thesefindingsalsosupportthe
hypothesis that variations in the duration of 17b-E2
primingcanaffecttheresponseoftheendometriumto
P and therefore the subsequent implantation process
[11, 22].
The number of implantation-associated gene tran-
scripts,however,wasratherlow.Thiscouldbebecause
the culturing of explants alters the physiology of the
tissue and therefore its steroid responsiveness or
because, as shown for prolactin and IGFBP1, in some
cases prolonged exposure to P is required for genes to
respond [23]; the latter finding is supported by a
report from Kao and coworkers showing that many
genes up-regulated in the implantation window are
not yet regulated in ES endometrium, at which time
the endometrium has been exposed to P for only a
short time [21]. Explant cultures are therefore appro-
priate models to study immediate responses of human
endometriumtooestrogensandprogestinsexvivobut
do not allow investigation of the entire spectrum of
implantation-associated genes.
The low number of implantation-related genes iden-
tifiedmayalsobearesultoftherelativelylownumber
of samples used for the initial microarray hybrid-
izations, which increases the likelihood of missing
relevant genes and the chance of generating false
positives. At the time the microarray experiments
were performed, we opted to carry out a limited
number of array hybridizations so that we could apply
rigorous statistical procedures and perform extensive
validationofselectedgenesforboththearraysamples
and samples from additional independent experi-
ments. Rockett and Hellmann asked the questions:
how many genes should we pick for validation, and
which genes should we pick? The authors argue that
genes can be selected to ensure successful confirma-
tion, i.e. by selecting genes that have changed more
than 4-fold [24] or by selecting genes that have been








alkaline phosphatase, placental (Regan isozyme) ALPP 10.00 4.79 NM_001632.2 metabolism
apolipoprotein D APOD 3.09 4.90 NM_001647.1 transport
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 CHST7 4.57 7.08 NM_019886.1 metabolism
cytochrome P450, family 26, subfamily A, polypeptide 1 CYP26A1 4.68 33.11 NM_000783.1 transport
GREB1 protein GREB1 2.69 2.24 NM_014668.1 unknown
insulin-like growth factor binding protein 1 IGFBP1 2.19 2.45 NM_000596.1 signal
transduction
secretoglobin, family 1D, member 2 SCGB1D2 60.26 10.00 NM_006551.2 unknown
secretoglobin, family 2A, member 1 SCGB2A1 6.92 2.63 NM_002407.1 signal
transduction
solute carrier family 7 (cationic amino acid transporter, y+
system), member 8
SLC7A8 2.75 4.37 NM_012244.1 transport
chromosome 20 open reading frame 42 C20orf42 2.82 2.82 NM_017671.1 unknown
cystic fibrosis transmembrane conductance regulator CFTR 8.32 4.07 NM_000492.2 transport
hypothetical protein FLJ11082 FLJ11082 2.88 2.04 NM_018317.1 unknown
integrin, beta 6 ITGB6 2.75 2.95 NM_000888.3 cell adhesion
latexin protein LXN 2.63 2.51 NM_020169.1 unknown
Gene transcripts regulated (2-fold) by 17b-oestradiol and progesterone (17b-E2+P) in both menstrual (M) and late proliferative (LP)
phase explants when compared to their respective vehicle-treated controls. Data are presented as fold changes.
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[25]. We selected six genes primarily based on the fact
thattheirexpressionisalteredduringtheimplantation
window. In addition, we selected two genes that have
not yet been reported in the endometrium. With the
exception of DKK1 (more than 5-fold induction), the
expression of the selected genes changed less than 3-
fold. We could confirm steroid regulation for four of
eight genes in independent experiments, which justi-
fies our approach.
Rockett and Hellmann also questioned the additive
value of corroborating the findings of microarray
experiments with alternative means of quantitating
themRNAabundanceofalimitednumberofgenesof
the array [25]. The vast majority of studies published
state that the DNA array data can be corroborated,
indicatingthatthearraydataarereliableaslongasthe
experimental design and statistical analysis is sound.
Even in high-impact journals, studies that have not
been validated are being published; Goodman illus-
tratedthisbyshowingthatourof28microarraypapers
in Science, Cell and Nature published in 2002, only 11
reported corroborative studies [26]. It is evident that
clear standards, such as the guideline Minimal In-
formation about a Microarray Experiment
(MIAME), in the confirmatory studies area are
necessary [25].
A clear distinction could be made between genes that
are regulated by P irrespective of the presence of 17b-
E2 and genes for which the expression is clearly
influenced by the continuous presence of 17b-E2.
Many genes modulated by P alone were similarly
modulated in the 17b-E2+P-treated explants (119/161
P-modulated genes), however, 42 of the P-modulated
genes were not affected in the 17b-E2+P-treated
explants.Also,of the 219 17b-E2+P-modulated genes,
117 were not modulated by treatment with P alone.
Thisclearlyindicatesthattheexpressionofasubsetof
genesissensitivetothecontinuingpresenceof17b-E2.
It also indicates that in vivo priming of CD12 and
CD13 endometrium is remembered by the tissue in
vitro,leadingtosimilarexpression patternsforcertain
genes induced both in the absence and presence of
17b-E2.
A good example of genes for which expression is
known to be suppressed by P, but which were only
suppressed by P in the presence of 17b-E2, are various
members of the MMP family [12–14]. Only the
expression of MMP11 was suppressed by P alone;
the expression of MMP1, -3, -14 and -27 was only
suppressed in the presence of 17b-E2. Similarly, cystic
fibrosis transmembrane conductance regulator
(CFTR)wassuppressedin17b-E2+P-treatedexplants
but not in P-treated explants, suggesting that contin-
ued presence of 17b-E2 is required for the down-
regulationofCFTR.Thiscorrespondswiththefinding
that CFTR is highly expressed in the human endome-
trium around the ovulatory period [27] and is respon-
sive to both 17b-E2 and P.
Some genes were induced by 17b-E2+P in both
menstrual and late proliferative phase explants (i.e.
alkaline phosphatase, ALPP; monoamine oxidase,
MAOA; secretoglobin family 1, member D,
SCGB1D2; CFTR; P450 cytochrome family 26 sub-
family A, CYP26A), indicating that the expression of
these genes does not depend on prolonged in vivo
oestrogenprimingoftheendometrium.Aparticularly
interesting observation in this regard is the up-
regulation of expression of the CYP26A gene in
both menstrual and late proliferative phase endome-
trium by 17b-E2+P and, to a lesser extent, by P alone.
This enzyme is responsible for the metabolism of the
active retinoid metabolite all-trans retinoic acid. The
importance of controlling retinoid levels in the uterus
is illustrated by the fact that vitamin A deficiency in
women,nonhumanprimatesandlaboratoryanimalsis
associated with pregnancy failure and developmental
defects [28–30], whereas excess vitamin A levels are
detrimental to blastocyst development [31] and the
decidualization process [32].
Uterine vitamin A levels in women increase in the
presence of oestrogens [33, 34], most likely as the
result of up-regulation of retinaldehyde dehydrogen-
ase (RALDH2), a critical enzyme in retinoic acid
(RA) biosynthesis [35]. Since retinoids are morpho-
gens and essential for epithelial cell growth [36], they
may be involved in the regeneration, growth and
differentiation of the endometrial epithelium after
menstruation. The induction of CYP26A expression
by P in the secretory phase most likely serves to
inactivate excessive amounts of retinoids.
Databases can be explored with several different
bioinformaticstools.WehaveemployedtheIngenuity
Pathways Analysis (IPA) program, which has the
added advantage that it is an evidence-based data
mining tool. In contrast to most other bioinformatics
tools, which annotate certain functions to gene
products, the IPA program includes any reported
interaction between two genes, whether it involves
regulation of gene or protein expression, protein-
protein interactions or enzymatic conversion (for
example, phosphorylation). It is therefore a continu-
ously growing database and, by the nature of its
development, not complete. It is not unusual that the
mostaffectedgenesarenotpresentedinthenetworks.
The networks present groups of genes that have a
proven biological relationship. The nodes in these
highly significant networks presumably represent
genes that have important modulatory roles. When
interpreting the data, one has to realize that the IPA
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more attention than others and therefore have a
higher likelihood to be included in a network. How-
ever, the continuously growing database will allow re-
analysis of the data in the future, which may reveal
novel unidentified relationships between genes or
groups of genes.
The significant suppressive actions of P on nodes
representing immunomodulators were immediately
apparent; these included IL-1b, IL-8, COX2, the
chemokine CCL5 and members of the TGF-b super-
family (TGF-b2 and -3, INHBA and their signalling
moleculesSMAD2and-3).Attheendofthesecretory
phase, a rapid influx of leukocytes, consisting mostly
of NK cells and macrophages, into the endometrium
can be observed; this is believed to be the result of the
disappearance of P suppression on key inflammatory
mediators [37, 38]. Apparently, these immunosup-
pressiveactionsofPcanatleastpartlybemimickedin
the explant model by short-term incubation with 17b-
E2 and P.
One of the few nodes present in highly significant
networks identified by the IPA program in both 17b-
E2- and P-treated menstrual and late proliferative
phase endometrium was FGF2 or basic fibroblast
growth factor (bFGF). FGF2 expression is sup-
pressed by P. The significance of this finding is
illustrated by the fact that FGF2 inhibits the decidu-
alization process in human endometrial stromal cells
[39] and should therefore be controlled by P during
the secretory phase. FGF2 is an important mitogenic
and angiogenic factor that is expressed as different
isoforms synthesized through the alternative use of
translation initiation codons [40]. In human endo-
metrium, only the smallest 18-kD isoform is present
[41].Itislocatedpredominantlyinthecytoplasmand
is stored in the extracellular matrix [42]. FGF2 is
released mostly during menstruation and the early
proliferative phase and is expressed in blood vessels
throughout the menstrual cycle [41, 43]. The FGF
receptors, however, are not expressed in blood
vessels except during the MS (FGFR2) and late
secretory phases (FGFR1 and FGFR2). Blood ves-
sels may therefore not be the main target of FGF2.




to regulate proliferation of various cell populations
of the bone marrow [44], which were shown to be of
eminent importance for regeneration of the human
endometrium [45].
Inconclusion,explantcultureofhumanendometrium
is a biologically relevant in vitro model system that
allows the investigation of steroid regulation of gene
expression in the tissue context. Regulation of the
expression of several genes associated with embryo
implantation can be mimicked in vitro. We showed
that expression of thrombomodulin, monoamine
oxidase A and SPARCL1 is regulated by progestins.
Only a subset of implantation-associated genes was
modulated in the short-term explant cultures; how-
ever, we clearly showed that we can distinguish genes
thatrequirecontinuouspresenceof17b-E2 fromthose
that depend on P only. Therefore, 17b-E2 selectively
primes implantation-related genes for the effects of P.
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